Viral pneumonia.

Department of Paediatrics, Turku University Hospitals, Turku, Finland.
The Lancet (Impact Factor: 45.22). 03/2011; 377(9773):1264-75. DOI: 10.1016/S0140-6736(10)61459-6
Source: PubMed

ABSTRACT About 200 million cases of viral community-acquired pneumonia occur every year-100 million in children and 100 million in adults. Molecular diagnostic tests have greatly increased our understanding of the role of viruses in pneumonia, and findings indicate that the incidence of viral pneumonia has been underestimated. In children, respiratory syncytial virus, rhinovirus, human metapneumovirus, human bocavirus, and parainfluenza viruses are the agents identified most frequently in both developed and developing countries. Dual viral infections are common, and a third of children have evidence of viral-bacterial co-infection. In adults, viruses are the putative causative agents in a third of cases of community-acquired pneumonia, in particular influenza viruses, rhinoviruses, and coronaviruses. Bacteria continue to have a predominant role in adults with pneumonia. Presence of viral epidemics in the community, patient's age, speed of onset of illness, symptoms, biomarkers, radiographic changes, and response to treatment can help differentiate viral from bacterial pneumonia. However, no clinical algorithm exists that will distinguish clearly the cause of pneumonia. No clear consensus has been reached about whether patients with obvious viral community-acquired pneumonia need to be treated with antibiotics. Apart from neuraminidase inhibitors for pneumonia caused by influenza viruses, there is no clear role for use of specific antivirals to treat viral community-acquired pneumonia. Influenza vaccines are the only available specific preventive measures. Further studies are needed to better understand the cause and pathogenesis of community-acquired pneumonia. Furthermore, regional differences in cause of pneumonia should be investigated, in particular to obtain more data from developing countries.

Download full-text


Available from: Olli Ruuskanen, Jan 13, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Quantitative real-time polymerase chain reaction (qRT-PCR) assay of the upper respiratory tract is used increasingly to diagnose lower respiratory tract infections. The cycle threshold (CT ) values of qRT-PCR are continuous, semi-quantitative measurements of viral load, although interpretation of diagnostic qRT-PCR results are often categorized as positive, indeterminate, or negative, obscuring potentially useful clinical interpretation of CT values. From 2008 to 2010, naso/oropharyngeal swabs were collected from outpatients with influenza-like illness, inpatients with severe respiratory illness, and asymptomatic controls in rural Kenya. CT values of positive specimens (i.e., CT values < 40.0) were compared by clinical severity category for five viruses using Mann-Whitney U-test and logistic regression. Among children <5 years old we tested with respiratory syncytial virus (RSV), inpatients had lower median CT values (27.2) than controls (35.8, P = 0.008) and outpatients (34.7, P < 0.001). Among children and older patients infected with influenza virus, outpatients had the lowest median CT values (29.8 and 24.1, respectively) compared with controls (P = 0.193 for children, P < 0.001 for older participants) and inpatients (P = 0.009 for children, P < 0.001 for older participants). All differences remained significant in logistic regression when controlling for age, days since onset, and coinfection. CT values were similar for adenovirus, human metapneumovirus, and parainfluenza virus in all severity groups. In conclusion, the CT values from the qRT-PCR of upper respiratory tract specimens were associated with clinical severity for some respiratory viruses. J. Med. Virol. 85:924-932, 2013. © 2013 Wiley Periodicals, Inc.
    Journal of Medical Virology 05/2013; 85(5):924-932. DOI:10.1002/jmv.23455 · 2.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The diagnostics of respiratory viral infections has improved markedly during the last 15 years with the development of PCR techniques. Since 1997, several new respiratory viruses and their subgroups have been discovered: influenza A viruses H5N1 and H1N1, human metapneumovirus, coronaviruses SARS, NL63 and HKU1, human bocavirus, human rhinoviruses C and D and potential respiratory pathogens, the KI and WU polyomaviruses and the torque teno virus. The detection of previously known viruses has also improved. Currently, a viral cause of respiratory illness is almost exclusively identifiable in children, but in the elderly, the detection rates of a viral etiology are below 40%, and this holds also true for exacerbations of chronic respiratory illnesses. The new viruses cause respiratory symptoms like the common cold, cough, bronchitis, bronchiolitis, exacerbations of asthma and chronic obstructive pulmonary disease and pneumonia. Acute respiratory failure may occur. These viruses are distributed throughout the globe and affect people of all ages. Data regarding these viruses and the elderly are scarce. This review introduces these new viruses and reviews their clinical significance, especially with regard to the elderly population.
    The Open Respiratory Medicine Journal 07/2011; 5:61-9. DOI:10.2174/1874306401105010061
  • [Show abstract] [Hide abstract]
    ABSTRACT: L’attention des réanimateurs n’est guère attirée par les bactéries atypiques ou les virus dans le cadre des pneumonies communautaires sévères. Seules classiquement, Legionella pneumophila et les virus influenza, du fait de la pandémie grippale récente H1N1, restent présents dans la réflexion diagnostique. Pourtant, les pneumonies bactériennes atypiques ne sont pas rares, représentant jusqu’à 44 % des pneumonies communautaires. Considérées comme moins sévères que les pneumonies à bactéries pyogènes « typiques », 25 % d’entre elles justifient une hospitalisation, et 15 % présentent des critères de sepsis sévères. Si Legionella pneumophila est plus fréquemment en cause dans les formes graves, Mycoplasma pneumoniae peut être responsable de véritables défaillances multiviscérales. Les outils diagnostiques sont aujourd’hui performants (antigénurie légionelle et recherche en polymerase chain reaction [PCR] de mycoplasme en particulier) et permettent un diagnostic rapide et précoce. Le traitement est bien codifié et repose sur les macrolides ou les fluoroquinolones, en association dans les formes graves de légionellose. Le rôle des virus au cours des pneumonies communautaires sévères, seuls ou associés à des bactéries, devient de plus en plus établi grâce aux méthodes de diagnostic rapide de biologie moléculaire. Ces techniques ont permis la mise en évidence dans ces pneumonies de nombreux et nouveaux virus. Toute la question est désormais à l’imputabilité clinique de ces résultats biologiques très performants et donc à la décision d’instaurer ou non un traitement antiviral dont l’efficacité dans les formes sévères reste discutable.
    Réanimation 01/2013; 22(1). DOI:10.1007/s13546-012-0634-y